NASHVILLE, Tennessee—Monogram Health, a value-based specialty provider of in-home evidence-based care and benefit management services for patients living with polychronic conditions, including chronic kidney and end-stage renal disease, has closed on $375 million of new funding. This growth funding round included investments from strategic investors CVS Health, Cigna Ventures, Humana, Memorial Hermann Health System and SCAN, as well as from both new and existing financial investors including TPG Capital, Frist Cressey Ventures, Heritage Group, Pura Vida Investments and Norwest Venture Partners, among others.
Monogram will use the proceeds to deploy the company's in-home kidney and polychronic care delivery model and clinical services, which include complex case and disease management, utilization management and medication therapy management. Monogram says its model of care changes the way health care is delivered for those with kidney disease and has been shown to improve patient outcomes and quality of life while reducing medical costs.
"Monogram is bringing an innovative, integrated approach to in-home care delivery that is increasing access and engagement, lowering cost, and driving better outcomes for patients managing chronic kidney disease," said Todd Sisitsky, president of TPG and co-managing Partner of TPG Capital.
For the more than 37 million American adults living with chronic kidney disease, access to the type of specialized care that Monogram provides is critical. Monogram's in-home model is driven by the company's extensive market-based teams of clinicians, led by physicians and nurse practitioners who are supported by registered nurses, social workers, pharmacists and care management teams. These providers and clinical experts are further bolstered by utilization management teams that focus in and around hospitalizations and discharge management, personalizing the experience and care for Monogram patients in nearly 4,000 U.S. cities across 34 states.
"Everything we do is designed to improve access to health care and health outcomes for polychronic patients by supporting their individual needs in their own homes, transforming the patient experience, especially for those who have been historically underserved," said Mike Uchrin, CEO and co-founder of Monogram Health.
Monogram's investor base now serves over 30% of Medicare Advantage members nationwide and supports upwards of 40% of the U.S. population, uniquely positioning the company to serve those living with chronic kidney disease and their related metabolic disorders.
